The Russian Direct Investment Fund (RDIF), which is one of the developers of the Sputnik V, has submitted applications to the World Health Organization (WHO) for an Emergency Use Listing and prequalification of the coronavirus vaccine.
The acceptance of the Covid-19 vaccine by the UN health agency could help allay concerns over its safety and quality.
This was disclosed by Russia’s sovereign wealth fund on Tuesday, October 27, 2020.
Russia was the first country to grant regulatory approval for a novel coronavirus vaccine and did so before large-scale trials were complete, stirring concerns among scientists and doctors about the safety and efficacy of the shot, especially from the western countries.
An Emergency Use Listing (EUL) is meant to make a vaccine available globally faster, while a WHO prequalification is a global quality tag that ensures vaccines are safe and effective.
The Chief Executive Officer of RDIF, Kirill Dmitriev, in a statement, pointed out that the procedures would allow Sputnik V to be included in the list of medical products that meet leading quality, safety and efficacy standards.
In July, Dmitriev had said that Russia aimed to produce 30 million doses in 2020, a goal that was this month dubbed impossible by Russia’s Industry Minister, Denis Manturov, who said a maximum of 2.3 million doses would be made.
The vaccine, developed by Moscow’s Gamaleya Research Institute and marketed by RDIF, is based on a platform of human adenoviral vectors.
What you should know
Nairametrics had earlier reported that President Vladimir Putin announced the approval of the Sputnik V, as the first Covid-19 vaccine to be registered in the world. The approval, which was announced even before the completion of the phase 3 trials, had elicited safety concerns from scientists.